Fig. 7
Combination of PRV-LAV with immune checkpoint inhibitors. A Timeline of the experimental setup. B-E Changes in the injected (B) and distant (C) tumor volumes curves for mice bearing CT26 tumors treated with vehicle, anti-PD1 antibody (5 mg/kg, intraperitoneally), anti-CTLA4 antibody (5 mg/kg, intraperitoneally), PRV-LAV (5 × 106 PFUs, intratumorally), and or different combinations. Changes in the tumor volumes are expressed as the mean ± SEM values (n = 6). In (B) and (C), statistical analysis was performed by repeated measure ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. Changes in the injected (D) and distant (E) tumor volume curves for each mouse are shown in (B-C). Complete response (CR) means the tumor has been cleared during the observation period. Partial response (PR) means tumor growth has been inhibited and less than 70% of the maximum tumor volume during the observation period. F Timeline of the experimental setup. G-H Changes in the tumor volume curves (G) and Kaplan–Meier survival curves (H) for mice bearing CT26 tumors treated with vehicle, anti-PD1 antibody (5 mg/kg, intraperitoneally), PRV-LAV (4 × 10.7 PFUs, intravenously), and the combination. Changes in the tumor volumes are expressed as the mean ± SEM values (n = 6). In (G) statistical analysis was performed by repeated measure ANOVA. Statistical analysis was performed using the log-rank test in (H). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001